The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | The role of immunotherapy in non-transplant eligible multiple myeloma
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, discusses the role of immunotherapy in non-transplant eligible multiple myeloma. Twenty years ago, there was no treatment that non-transplant eligible patients could benefit from. Today with the development of novel drugs, the heterogeneous population can be treated on an individual basis. Immunotherapy has transformed myeloma, but there are further developments to come in the future for both transplant and non-transplant eligible patients. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
